Of these, sensitizing EGFR mutations, ALK and ROS1 rearrangements as well as BRAF mutations have targeted therapies approved by the US Food and Drug Administration (FDA) in NSCLC (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.